Direkt zum Inhalt
Merck

04-739

Anti-C-RAF antibody

rabbit monoclonal, AM223

Synonym(e):

Oncogene RAF1, raf proto-oncogene serine/threonine protein kinase, v-raf-1 murine leukemia viral oncogene homolog 1

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

100 μL

€ 463,00

€ 463,00


Warenkorb auf Verfügbarkeit prüfen
Für Ihr Target ist ein rekombinanter, konservierungsmittelfreier Antikörper verfügbar. Probieren Sie ZRB1606

Großbestellung anfragen

Über diesen Artikel

UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

Produktname

Anti-Raf-1 Antibody, clone AM223, rabbit monoclonal, culture supernatant, clone AM223, from rabbit

biological source

rabbit

antibody form

culture supernatant

clone

AM223, monoclonal

species reactivity

human, mouse, rat

technique(s)

immunoprecipitation (IP): suitable
western blot: suitable

isotype

IgG

NCBI accession no.

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Quality Level

Gene Information

human ... RAF1(5894)

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
SAB5700603SAB5700561SAB5700373
species reactivity

human, mouse, rat

species reactivity

mouse, rat, human

species reactivity

human

species reactivity

mouse, human, rat

clone

AM223, monoclonal

clone

polyclonal

clone

polyclonal

clone

polyclonal

Gene Information

human ... RAF1(5894)

Gene Information

human ... RAF1(5894)

Gene Information

human ... RAF1(5894)

Gene Information

human ... RAF1(5894)

antibody form

culture supernatant

antibody form

affinity isolated antibody

antibody form

affinity isolated antibody

antibody form

affinity isolated antibody

biological source

rabbit

biological source

rabbit

biological source

rabbit

biological source

rabbit

shipped in

dry ice

shipped in

wet ice

shipped in

wet ice

shipped in

wet ice

Analysis Note

Control
Positive Antigen Control: Catalog #12-305, 3T3/A31 lysate. Add 2.5 μL of 2-mercapto-ethanol/100 μL of lysate and boil for 5 minutes to reduce the preparation. Load 20 μg of reduced lysate per lane for minigels.
Routinely evaluated by Western Blot on 3T3/A31 lysates.

Application

Anti-Raf-1 Antibody, clone AM223 is an antibody against Raf-1 for use in IP & WB.
Research Category
Signaling
Research Sub Category
MAP Kinases
Western Blotting Analysis:
A 1:500-1:2,000 diltuoin of this lot detected Raf-1 in 3T3/A31 cell lysates.

Immunoprecipitation: 2-4 μg of a previous lot immunoprecipitated Raf-1 from 400 μg of 3T3/A31 RIPA lysate.

Biochem/physiol Actions

Predicted to cross-react with rat based on sequence homology.
Recognizes Raf-1, Mr 74 kDa.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

74 kDa
The Raf proteins (Raf-1, A-Raf, B-Raf) are Ser/Thr kinases with homology to the PKC family, containing an N-terminal regulatory domain and a c-terminal catalytic domain. Members of the Raf family bind to activated Ras GTPase, which results in Raf translocation to the plasma membrane and activation. Activated Raf proteins phosphorylate MEKs, and are therefore the principle transducers of signals from Ras to MAP kinase. In addition to its role in mitogenesis, Raf-1 may play a role in regulation of apoptosis and cell cycle progression. Activation of Raf-1 involves phosphorylation of Ser338/339 and Tyr340/341. Activating mutations of B-Raf that disrupt its auto-inhibition loop have been implicated in a number of cancers, including melanoma and colon cancer.

Preparation Note

Stable for 1 year at -20ºC from date of receipt.
Handling Recommendations: Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.

Immunogen

Epitope: C-terminus
KLH-conjugated, synthetic peptide corresponding to the C-terminus (amino acids 637-648 (CTLTTSPRLPVF)) of human Raf-1.

Other Notes

Replaces: 04-412

Physical form

Cultured supernatant with 0.05% sodium azide.

Lagerklasse

12 - Non Combustible Liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Malgorzata Milewska et al.
Therapeutic advances in medical oncology, 10, 1758834017746040-1758834017746040 (2018-02-01)
The application of genomic technologies to patient tumor samples identified groups of signaling pathways which acquire activating mutations. Some cancers are dependent on these mutations and the aberrant proteins resulting from these mutations can be targeted by novel drugs which
Andreas R Baudy et al.
EJNMMI research, 2(1), 22-22 (2012-06-02)
The BRAF inhibitor, vemurafenib, has recently been approved for the treatment of metastatic melanoma in patients harboring BRAFV600 mutations. Currently, dual BRAF and MEK inhibition are ongoing in clinical trials with the goal of overcoming the acquired resistance that has
Naomi Elster et al.
Therapeutic advances in medical oncology, 10, 1758835918778297-1758835918778297 (2018-07-20)
Somatic mutations in the ERBB genes (epidermal growth factor receptor: EGFR, ERBB2, ERBB3, ERBB4) promote oncogenesis and lapatinib resistance in metastatic HER2+ (human epidermal growth factor-like receptor 2) breast cancer in vitro. Our study aimed to determine the frequency of
Patrick Kwok-Shing Ng et al.
Cancer cell, 33(3), 450-462 (2018-03-14)
The functional impact of the vast majority of cancer somatic mutations remains unknown, representing a critical knowledge gap for implementing precision oncology. Here, we report the development of a moderate-throughput functional genomic platform consisting of efficient mutant generation, sensitive viability
Kelli-Ann Monaco et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(7), 2061-2073 (2020-12-24)
Targeting RAF for antitumor therapy in RAS-mutant tumors holds promise. Herein, we describe in detail novel properties of the type II RAF inhibitor, LXH254. LXH254 was profiled in biochemical, in vitro, and in vivo assays, including examining the activities of

Questions

Reviews

No rating value

Active Filters

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung